CA2202630A1 - Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis - Google Patents
Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosisInfo
- Publication number
- CA2202630A1 CA2202630A1 CA002202630A CA2202630A CA2202630A1 CA 2202630 A1 CA2202630 A1 CA 2202630A1 CA 002202630 A CA002202630 A CA 002202630A CA 2202630 A CA2202630 A CA 2202630A CA 2202630 A1 CA2202630 A1 CA 2202630A1
- Authority
- CA
- Canada
- Prior art keywords
- zaprinast
- cgmp
- cells
- day
- intimal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229950005371 zaprinast Drugs 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 title claims description 9
- 230000002401 inhibitory effect Effects 0.000 title claims description 5
- 208000037803 restenosis Diseases 0.000 title description 7
- 230000002792 vascular Effects 0.000 title description 6
- 238000004519 manufacturing process Methods 0.000 title description 3
- 238000002399 angioplasty Methods 0.000 claims abstract description 18
- 206010020718 hyperplasia Diseases 0.000 claims abstract description 15
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 abstract description 10
- 206010060965 Arterial stenosis Diseases 0.000 abstract description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 20
- 241000700159 Rattus Species 0.000 description 20
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 11
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 230000029142 excretion Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 230000002485 urinary effect Effects 0.000 description 7
- 210000001715 carotid artery Anatomy 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 description 5
- 101800000060 C-type natriuretic peptide Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 206010051113 Arterial restenosis Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 206010003162 Arterial injury Diseases 0.000 description 2
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- 108020001621 Natriuretic Peptide Proteins 0.000 description 2
- 102000004571 Natriuretic peptide Human genes 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000692 natriuretic peptide Substances 0.000 description 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KFMVHONQQFRNNH-UHFFFAOYSA-N 5-(2-propoxyphenyl)triazolo[4,5-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NN=NC2=N1 KFMVHONQQFRNNH-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- -1 ANF (23) Chemical compound 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000017178 Guanylate Cyclase-Coupled Receptors Human genes 0.000 description 1
- 108010013990 Guanylate Cyclase-Coupled Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000004145 Methyl glucoside-coconut oil ester Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- UASRYODFRYWBRC-UHFFFAOYSA-N cGMP Natural products N1C(N)=NC(=O)C2=C1N(C1C3OP(O)(=O)OC3C(CO)O1)C=N2 UASRYODFRYWBRC-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000013156 embolectomy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000005048 flame photometry Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000008069 intimal proliferation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000027849 smooth muscle hyperplasia Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
A method is disclosed for treatment of arterial stenosis which comprises administering to a warm-blooded mammal following balloon angioplasty a small but effective amount of zaprinast sufficient to inhibit intimal hyperplasia in said mammal.
Description
W O 96/11688 ~ 5/12366 USE OF ZAPRINAST FOR THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING VASCULAR
RESTENOSIS
Backqround of the Invention The present invention relates to a method for the treatment of arterial stenosis and, more particularly, to a method of inhibiting intimal hyperplasia following balloon angioplasty by treatment with zaprinast.
(NOTE: Literature reference~ on the following background information and on the conventional te~t method~ and laboratory procedureQ well known to the per~on _killed in the art and other such ~tate-of-the-art techn;que~ as u~ed herein are indicated in parenthe~e~ andappended at the end of the ~pecification.) Balloon angioplasty is a widely used medical procedure with an initial success rate of greater than ninety percent (26). Success is defined as a reduction of the original stenosis by more than fifty percent.
However, arterial restenosis is a significant complication and occurs in approximately 17-40% of all patients (1-5). M~ch~n;~c contributing to vascular restenosis include platelet aggregation (27), local vasoconstriction (28), and intimal proliferation of smooth muscle cells. Treatment with anti-coagulants (29), smooth muscle vasodilators (30), and anti-proliferative agents (31) have not successfully inhibited clinical restenosis. Recently, it has been suggested that activation of the vascular renin angiotensin system (RAS) in diseased vessels stimulates intimal smooth muscle hyperplasia (32). Human trials evaluating angiotensin converting enzyme inhibitors for arterial restenosis have not been successful (33), but further trials are ongoing.
Intimal hyperplasia has been described in part as an uncontrolled growth response of vascular smooth muscle cells (VSMCs) following vascular reconstructions (e.g. balloon angioplasty and bypass grafting) and is a leading cause of surgical reintervention for restenosis (1-5). Although there is no available therapy to prevent the formation of intimal hyperplasia, recent advancements were made by McNamara and colleagues (6).
They demonstrated that the intimal proliferative response was inhibited by altering the level of the naturally occurring metabolite nitric oxide (NO) with L-arginine a~in;~tration in animal models of balloonangioplasty. Their hypothesis was that NO, formed by the vascular endothelium, would inhibit intimal hyperplasia similar to its ability to inhibit VSMC
proliferation in vitro (7-9). In addition, Furuya and colleagues (10) recently showed that a~m;n;~tering C-type natriuretic peptide (CNP) also attenuated intimal thickening after vascular injury in rats.
CNP is a member of the natriuretic family of peptides which also includes atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). `CNP is synthesized in the vascular endothelial cell (11,12), and its receptor, guanylyl cyclase type B (GC-B), is expressed in the vascular smooth muscle cell (13,14).
Quiescent smooth muscle cells express ~;~ l amounts of GC-B; however, during growth and replication GC-B
expression is dramatically increased both in vitro (13,14) and in vivo (10). CNP, like NO, increases intracellular cGMP upon receptor activation, and potently inhibits cellular proliferation and DNA
synthesis in cultured rat VSMCs (15,16). HQwever, since some of the biologies of NO and the natriuretic peptides have been attributed to non-cGMP mediated mechanisms (17), the present inventor sought to evaluate the role of cellular CGMP in the proliferative and growth response of VSMCs. One means to increase cellular CGMP
levels is to inhibit its degradation to its 5'-monophosphate. Cyclic-AMP and cGMP are metabolized by cellular phosphodiesterase enzymes. Currently, five specific classes of enzymes have been defined. The type five enzyme is a cGMP specific phosphodiesterase designated as PDE-V.
Brief DescriPtion of the Invention In accordance with the present invention, a method is provided for inhibiting intimal hyperplasia.
The method comprises parenterally administering to a warm-blooded mammal following balloon angioplasty a small but effective amount of zaprinast. zaprinast is the generic name of 1,4-dihydro-5-[2-propoxyphenyl]-7H-1,2,3-triazolo[4,5-d]pyrimidine-7-one, which is also known chemically as 2-o-propoxyphenyl-8-azapurin-6-one (M~B 22948).
Zaprinast is a known selective inhibitor of the cyclic-GMP-specific PDE (PDE-V) (18). It elevates cellular cGMP, and has been shown to potentiate the pharmacologic profile of both No (19) and the natriuretic peptides (20).
As illustrated herein, zaprinast has been found to inhibit vascular smooth muscle cell lVSMC) proliferation in vl tro and the intimal proliferative response induced by balloon angioplasty of rat carotid artery.
In cell culture, zaprinast (1 mM) inhibited serum-induced VSMC proliferation by 80~. In rat model of balloon angioplasty, continuous intravenous a~;nj~tration of zaprinast (2S mg/kg/day for 14 days, begun one day prior to arterial injury) inhibited the intimal lesion size by 51%. Zaprinast infusion had no effect on mean arterial pressure, while plasma cGMP
levels were elevated eight-fold. Urinary cGMP and WO 96/11688 . PCT/US95112366 sodium excretion was also significantly elevated with zaprinast treatment. Hence, inhibition of vascular cGMP
metabolism with zaprinast is an efficacious treatment of restenosis secondary to balloon angioplasty.
A significant advantage of zaprinast is that it is a small organic molecule that is readily absorbed (25). Based on the results shown herein, it is deemed to be useful in the inpatient or outpatient management of atherosclerosis and arterial restenosis.
It will be appreciated that although the method of the invention is illustrated in particular hereinbelow with the rat species, it is also useful for other warm-blooded mammals, e.g., humans, in an analogous manner.
Detailed DescriPtion of the Invention While the specification concludes with claims particularly pointing out and distinctly claiming the subject matter regarded as forming the present invention, it is believed that the invention will be better understood ~rom the following preferred embodiments of the invention taken in conjunction with the accompanying drawings.
Brief DescriPtion of the Drawinqs FIG.l shows the effect of zaprinast on rat aortic smooth muscle cell proliferation in culture. Cells were seeded at a density of 10,000 cells/well and incubated in the absence or presence of drug for three days.
Values are expressed as the mean + standard error of the mean of four individual determinations. Statistical significance was compared versus the no drug group.
_ _ _ _ _ . _ _ _ _ _ _ _ CA 02202630 l997-04-l4 FIGS. 2A and 2B show the effect of zaprinast on intimal hyperplasia in the rat. Rat carotid arteries were injured by balloon angioplasty on day one, then harvested for histology fourteen days later. Zaprinast infusion 25mg/kg/day was begun one day prior to injury and continued until animal sacrifice. FIG.2A shows intimal hyperplasia expressed as a function of intimal surface area, and FIG.2B shows intimal hyperplasia expressed as a function of the ratio of the intima to media surface area. Values are expressed as the mean st~n~A~d error of the mean of eight animals.
Statistical significance was compared versus vehicle infusion.
FIG. 3 shows representative histologic cross-sections of rat carotid artery after balloon angioplasty, (A) zaprinast-treated, 25X magnification;
(B) zaprinast-treated, lOX magnification; (C) vehicle-treated, 25X magnification; (D) vehicle-treated, lOX
magnification. a = vessel media, b = vessel intima.
FIG. 4 shows plasma cGMP concentrations in vehicle and zaprinast-treated rats. Plasma cGMP was measured in animals prior to and fourteen days after beginning vehicle or zaprinast infusions. Values are expressed as the mean + st~n~rd error of the mean of six rats. Statistical significance was compared between day zero and day fourteen within each treatment group.
In order to illustrate the invention in greater detail, the following specific laboratory examples were carried out. Although specific examples and details are illustrated herein, it will be appreciated that the invention is not limited to these specific examples or their details.
EXAMPLES
MAT~T~T~ AND METHODS
Cell Culture. Rat carotid VSMCs were isolated by conventional explant culture as previously described (21,22). VSMCs were grown in Dulbecco's Modified Eagle Medium (DMEM; Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; HyClone Labs Inc., Logan, FL), 100 units/ml penicillin, and 100 ~g/ml streptomycin and were passed 1:2 at confluence. To determine if the cultured cells were SMCs and not endothelial cells or fibroblasts, immunohistochemical staining was performed with antibodies to SMC specific a-actin and Factor VIII (Sigma Chemical Company, St.
Louis, MO). For all tests, cells were used at passage 10 to 15.
Cell Proliferation Assay. To determine the effect of zaprinast on SMC proliferation, cells were seeded at 10,000 cells per well on 6-well plates, and the cells were kept in growth-arrest medium for three days. Growth arrest medium consisted of 0.1% FBS-DMEM.
The medium was then changed to 10% FBS-DMEM, and various doses of zaprinast were added. The cells were permitted to grow for three days in the presence of zaprinast. At the end of this time, the cells were removed from the plates by trypsinization, and counted with a Coulter counter (Model AM; Coulter Electronics, Hialeah, FL).
Each experiment was done in quadruplicate and repeated at least two times.
Balloon Angioplasty and Drug Infusion. The procedure employed herein for carotid arterial injury is well known in the literature (21,22). Briefly, male Sprague-Dawley rats tweight 400-450 grams) were anesthetized with an intramuscular dose of ketamine (40 mg/kg), acepromazine (1 mg/kg), and xylazine (20 mg/kg) and aseptically prepped. An Alzet minipump (Alzet _ Corp., Palo Alto, CA) filled with either normal saline or zaprinast (50 mg/ml), was implanted subcutaneously in the animals' back and the infusion tubing was inserted into the femoral vein. On the following day, the animals were reanesthetized and a 3 French embolectomy catheter was inserted in the left external carotid artery through a midline incision to the neck.
Endothelial denudation and medial injury were performed by filling the balloon with 0.1 ml of saline and pulling it antegrade along the entire length of the artery three times to assure uniform injury. On day 14 post injury, the ~n;~ls were reanesthetized as described above.
Left carotid arteries were harvested, perfusion fixed with 4~ paraformaldehyde at physiologic pressures and processed for histology. Animal care complied with the "Principles of Laboratory Animal Care" and the "Guide for the Care and Use of Laboratory Animal" (NIH
Publication No. 80-23, revised 198S).
Histology. The perfusion-fixed arteries were embedded in paraffin and sectioned (2 ~m) every 5 mm.
The sections were stained with Verhoeff van Giesem.
Video images of the light microscopic slides (Zeiss microscope) were projected on a television monitor, total intimal and medial area determined by computer-aided planimetry (Microsystems, Boyce Scientific, St.
Louis, MO), and the intima : media area ratio determined.
Physiological parameters. ~n day zero prior to Alzet pump implantation and day 14 post angioplasty, - arterial blood pressure was measured in anesthetized animals with a Harvard blood pressure monitor (model VT-~ 15C). All animals were placed in metabolic cages one day prior to sacrifice (day 14) for 24-hour urine collections in order to quantitate urinary sodium and cGMP excretion. While in the metabolic cages, ~n;
were not fed but allowed free access to tap water.
WO 96/11688 . PCT/US95tl2366 During days one to thirteen, rats were fed standard rat chow (Purina) and allowed free access to tap water.
Urinary and plasma cGMP was measured using a commercial enzyme immunometric assay (EIA) (Caymen Chem., Ann Arbor, MI). Urine volume was measured gravimetrically, and urine sodium was determined by flame photometry (Instrumentation Laboratory, model 943).
Reagents. Zaprinast was kindly provided by the Monsanto Corporation (St. Louis, MO).
~ tatistics. Statistics were performed using the statistical analysis software package (Instat, GraphPad, San Diego. CA). All data were expressed as mean +
standard error of the mean (SEM). Statistical analysis was performed by two-way analysis of variance and student's t-test was used to evaluate the significance of difference. A probability of less than 0.05 was considered statistically significant.
It has been previously demonstrated that agents which stimulate the production of cGMP such as ANF (23), CNP (13), and NO donors (24) are able to inhibit proliferation of smooth muscle cells in culture.
Therefore, the initial tests were designed to evaluate whether the inhibition of PDE-V by zaprinast, thus increasing endogenous cellular levels of cGMP, would inhibit smooth muscle cell proliferation. Rat aortic smooth muscle cells were seeded at a density of 10,000 cells/well. In the presence of 10% FBS, cell number increased five-fold in three days (FIG.l). In the presence of growth arrest media, no cellular proliferation was noted. One millimolar zaprinast inhibited FBS-induced smooth muscle cell proliferation by approximately 80%, while one tenth this dose _9_ demonstrated little to no inhibition. Theoretically, it is possible that zaprinast treatment decreased the - h~r of cells by causing cellular toxicity or death.
This was not the case since all zaprinast-treated cells effectively excluded trypan blue. Furthermore, daily monitoring of the cell culture media demonstrated no floating or dead cells. These data demonstrate that cellular cGMP is an endogenous inhibitor of VSMC
hyperplasia.
_, Balloon angioplasty of an artery produces intimal thickening and many times results in a significant stenosis. The intimal thickening is secondary to migration of smooth muscle cells from the media into the intima, and subsequent intimal smooth muscle cell proliferation. Since it was demonstrated that zaprinast inhibits smooth muscle cell proliferation in vitro, it was next evaluated whether zaprinast would also inhibit intimal hyperplasia in the injured rat carotid artery.
Zaprinast was a~m; n; stered as a continuous intravenous infusion (25 mg/kg/day) beginning one day prior to angioplasty and continuing until the time of animal sacrifice. As depicted in FIG.2A, zaprinast significantly inhibited intimal hyperplasia by 45%.
Similarly, when intimal hyperplasia was expressed as the ratio of the surface area of the intima to the surface area of the media (microns2), zaprinast inhibited restenosis by 51% (FIG.2B). Representative histological cross-sections of carotid artery from rats treated with either zaprinast or vehicle are shown in FIG.3. These data demonstrate that inhibition of PDE-V with zaprinast is an effective modality to inhibit angioplasty-induced intimal hyperplasia in the rat.
-The pharmacologic profile of zaprinast in rats includes vasorelaxation and sodium excretion (25), but at much higher doses (200 mg/kg/day) than were administered herein. When administered at 25 WO96111688 PCT~S95/12366 mg/kg/day), zaprinast had no effect on mean arterial blood pressure (FIG.4). However, plasma cGMP levels were significantly elevated approximately eight-fold fourteen days after zaprinast treatment (FIG.5).
Therefore, these data confirm the continuous delivery of zaprinast to the rat for the full fourteen days of the test protocol.
Similar to ANF, zaprinast stimulates urinary sodium and cGMP excretion (25). Consistent with these findings, urinary sodium excretion was increased two-fold in the zaprinast treatment group. This natriuresis was accompanied by a similar increase in urinary cGMP
excretion (Table l).
TABLE l Treat~ent (m~q/day) ~ ~lcaMP/vi ) mean + 8EM mean + 8EN
Control 0.9 + o.l 33.0 + 5.5 Zaprinast 2.l + 0.4** 62.5 + lO.3**
** p ~ O . 05 TABLE l shows the urinary sodium and cGMP
excretion in vehicle and zaprinast-treated rats.
Animals were placed into individual metabolic cages 24 hours prior to sacrifice for urine collection.
The administration of the zaprinast to a host or patient subjected to balloon angioplasty can be carried out by conventional means, preferably in formulations with pharmaceutically acceptable diluents and carriers.
The amount to be administered must be an effective amount, that is, an amount which is medically beneficial -CA 02202630 l997-04-l4 but does not present toxic effects which overweigh the advantages which accompany its use.
It is expected that the adult human dose would range upward from about 100mg of the active drug in a daily dose less than about 100mg/Kg of body weight, and preferably in a daily dose of from about 1.5 to about 25mg/Kg of body weight. A suitable route of a~;n;~tration is orally in the form of capsules, tablets, syrups, elixirs and the like, although parenteral administration can also be used such as , e.g., intravenous administration in admixture with physiologic saline and/or suitable buffers. Appropriate formulations of the active drug in pharmaceutically acceptable diluents and carriers in therapeutic dosage form can be prepared by reference to general texts in the field well known to the person skilled in the art such as, e.g., Reminqton's Pharmaceutical Sciences, Ed.
Arthur Osol, 16th ed. 1980, Mack Publishing Co., Easton, PA, and 18th ed. 1990.
Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.
WO 96/11688 PCT/US9~/12366 REFERENCES
1. McBrite, W., Lange, R~., ~ Hillis LD. (1988) N. Engl. I. Mcd. 31t, 1734-1737.
RESTENOSIS
Backqround of the Invention The present invention relates to a method for the treatment of arterial stenosis and, more particularly, to a method of inhibiting intimal hyperplasia following balloon angioplasty by treatment with zaprinast.
(NOTE: Literature reference~ on the following background information and on the conventional te~t method~ and laboratory procedureQ well known to the per~on _killed in the art and other such ~tate-of-the-art techn;que~ as u~ed herein are indicated in parenthe~e~ andappended at the end of the ~pecification.) Balloon angioplasty is a widely used medical procedure with an initial success rate of greater than ninety percent (26). Success is defined as a reduction of the original stenosis by more than fifty percent.
However, arterial restenosis is a significant complication and occurs in approximately 17-40% of all patients (1-5). M~ch~n;~c contributing to vascular restenosis include platelet aggregation (27), local vasoconstriction (28), and intimal proliferation of smooth muscle cells. Treatment with anti-coagulants (29), smooth muscle vasodilators (30), and anti-proliferative agents (31) have not successfully inhibited clinical restenosis. Recently, it has been suggested that activation of the vascular renin angiotensin system (RAS) in diseased vessels stimulates intimal smooth muscle hyperplasia (32). Human trials evaluating angiotensin converting enzyme inhibitors for arterial restenosis have not been successful (33), but further trials are ongoing.
Intimal hyperplasia has been described in part as an uncontrolled growth response of vascular smooth muscle cells (VSMCs) following vascular reconstructions (e.g. balloon angioplasty and bypass grafting) and is a leading cause of surgical reintervention for restenosis (1-5). Although there is no available therapy to prevent the formation of intimal hyperplasia, recent advancements were made by McNamara and colleagues (6).
They demonstrated that the intimal proliferative response was inhibited by altering the level of the naturally occurring metabolite nitric oxide (NO) with L-arginine a~in;~tration in animal models of balloonangioplasty. Their hypothesis was that NO, formed by the vascular endothelium, would inhibit intimal hyperplasia similar to its ability to inhibit VSMC
proliferation in vitro (7-9). In addition, Furuya and colleagues (10) recently showed that a~m;n;~tering C-type natriuretic peptide (CNP) also attenuated intimal thickening after vascular injury in rats.
CNP is a member of the natriuretic family of peptides which also includes atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). `CNP is synthesized in the vascular endothelial cell (11,12), and its receptor, guanylyl cyclase type B (GC-B), is expressed in the vascular smooth muscle cell (13,14).
Quiescent smooth muscle cells express ~;~ l amounts of GC-B; however, during growth and replication GC-B
expression is dramatically increased both in vitro (13,14) and in vivo (10). CNP, like NO, increases intracellular cGMP upon receptor activation, and potently inhibits cellular proliferation and DNA
synthesis in cultured rat VSMCs (15,16). HQwever, since some of the biologies of NO and the natriuretic peptides have been attributed to non-cGMP mediated mechanisms (17), the present inventor sought to evaluate the role of cellular CGMP in the proliferative and growth response of VSMCs. One means to increase cellular CGMP
levels is to inhibit its degradation to its 5'-monophosphate. Cyclic-AMP and cGMP are metabolized by cellular phosphodiesterase enzymes. Currently, five specific classes of enzymes have been defined. The type five enzyme is a cGMP specific phosphodiesterase designated as PDE-V.
Brief DescriPtion of the Invention In accordance with the present invention, a method is provided for inhibiting intimal hyperplasia.
The method comprises parenterally administering to a warm-blooded mammal following balloon angioplasty a small but effective amount of zaprinast. zaprinast is the generic name of 1,4-dihydro-5-[2-propoxyphenyl]-7H-1,2,3-triazolo[4,5-d]pyrimidine-7-one, which is also known chemically as 2-o-propoxyphenyl-8-azapurin-6-one (M~B 22948).
Zaprinast is a known selective inhibitor of the cyclic-GMP-specific PDE (PDE-V) (18). It elevates cellular cGMP, and has been shown to potentiate the pharmacologic profile of both No (19) and the natriuretic peptides (20).
As illustrated herein, zaprinast has been found to inhibit vascular smooth muscle cell lVSMC) proliferation in vl tro and the intimal proliferative response induced by balloon angioplasty of rat carotid artery.
In cell culture, zaprinast (1 mM) inhibited serum-induced VSMC proliferation by 80~. In rat model of balloon angioplasty, continuous intravenous a~;nj~tration of zaprinast (2S mg/kg/day for 14 days, begun one day prior to arterial injury) inhibited the intimal lesion size by 51%. Zaprinast infusion had no effect on mean arterial pressure, while plasma cGMP
levels were elevated eight-fold. Urinary cGMP and WO 96/11688 . PCT/US95112366 sodium excretion was also significantly elevated with zaprinast treatment. Hence, inhibition of vascular cGMP
metabolism with zaprinast is an efficacious treatment of restenosis secondary to balloon angioplasty.
A significant advantage of zaprinast is that it is a small organic molecule that is readily absorbed (25). Based on the results shown herein, it is deemed to be useful in the inpatient or outpatient management of atherosclerosis and arterial restenosis.
It will be appreciated that although the method of the invention is illustrated in particular hereinbelow with the rat species, it is also useful for other warm-blooded mammals, e.g., humans, in an analogous manner.
Detailed DescriPtion of the Invention While the specification concludes with claims particularly pointing out and distinctly claiming the subject matter regarded as forming the present invention, it is believed that the invention will be better understood ~rom the following preferred embodiments of the invention taken in conjunction with the accompanying drawings.
Brief DescriPtion of the Drawinqs FIG.l shows the effect of zaprinast on rat aortic smooth muscle cell proliferation in culture. Cells were seeded at a density of 10,000 cells/well and incubated in the absence or presence of drug for three days.
Values are expressed as the mean + standard error of the mean of four individual determinations. Statistical significance was compared versus the no drug group.
_ _ _ _ _ . _ _ _ _ _ _ _ CA 02202630 l997-04-l4 FIGS. 2A and 2B show the effect of zaprinast on intimal hyperplasia in the rat. Rat carotid arteries were injured by balloon angioplasty on day one, then harvested for histology fourteen days later. Zaprinast infusion 25mg/kg/day was begun one day prior to injury and continued until animal sacrifice. FIG.2A shows intimal hyperplasia expressed as a function of intimal surface area, and FIG.2B shows intimal hyperplasia expressed as a function of the ratio of the intima to media surface area. Values are expressed as the mean st~n~A~d error of the mean of eight animals.
Statistical significance was compared versus vehicle infusion.
FIG. 3 shows representative histologic cross-sections of rat carotid artery after balloon angioplasty, (A) zaprinast-treated, 25X magnification;
(B) zaprinast-treated, lOX magnification; (C) vehicle-treated, 25X magnification; (D) vehicle-treated, lOX
magnification. a = vessel media, b = vessel intima.
FIG. 4 shows plasma cGMP concentrations in vehicle and zaprinast-treated rats. Plasma cGMP was measured in animals prior to and fourteen days after beginning vehicle or zaprinast infusions. Values are expressed as the mean + st~n~rd error of the mean of six rats. Statistical significance was compared between day zero and day fourteen within each treatment group.
In order to illustrate the invention in greater detail, the following specific laboratory examples were carried out. Although specific examples and details are illustrated herein, it will be appreciated that the invention is not limited to these specific examples or their details.
EXAMPLES
MAT~T~T~ AND METHODS
Cell Culture. Rat carotid VSMCs were isolated by conventional explant culture as previously described (21,22). VSMCs were grown in Dulbecco's Modified Eagle Medium (DMEM; Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; HyClone Labs Inc., Logan, FL), 100 units/ml penicillin, and 100 ~g/ml streptomycin and were passed 1:2 at confluence. To determine if the cultured cells were SMCs and not endothelial cells or fibroblasts, immunohistochemical staining was performed with antibodies to SMC specific a-actin and Factor VIII (Sigma Chemical Company, St.
Louis, MO). For all tests, cells were used at passage 10 to 15.
Cell Proliferation Assay. To determine the effect of zaprinast on SMC proliferation, cells were seeded at 10,000 cells per well on 6-well plates, and the cells were kept in growth-arrest medium for three days. Growth arrest medium consisted of 0.1% FBS-DMEM.
The medium was then changed to 10% FBS-DMEM, and various doses of zaprinast were added. The cells were permitted to grow for three days in the presence of zaprinast. At the end of this time, the cells were removed from the plates by trypsinization, and counted with a Coulter counter (Model AM; Coulter Electronics, Hialeah, FL).
Each experiment was done in quadruplicate and repeated at least two times.
Balloon Angioplasty and Drug Infusion. The procedure employed herein for carotid arterial injury is well known in the literature (21,22). Briefly, male Sprague-Dawley rats tweight 400-450 grams) were anesthetized with an intramuscular dose of ketamine (40 mg/kg), acepromazine (1 mg/kg), and xylazine (20 mg/kg) and aseptically prepped. An Alzet minipump (Alzet _ Corp., Palo Alto, CA) filled with either normal saline or zaprinast (50 mg/ml), was implanted subcutaneously in the animals' back and the infusion tubing was inserted into the femoral vein. On the following day, the animals were reanesthetized and a 3 French embolectomy catheter was inserted in the left external carotid artery through a midline incision to the neck.
Endothelial denudation and medial injury were performed by filling the balloon with 0.1 ml of saline and pulling it antegrade along the entire length of the artery three times to assure uniform injury. On day 14 post injury, the ~n;~ls were reanesthetized as described above.
Left carotid arteries were harvested, perfusion fixed with 4~ paraformaldehyde at physiologic pressures and processed for histology. Animal care complied with the "Principles of Laboratory Animal Care" and the "Guide for the Care and Use of Laboratory Animal" (NIH
Publication No. 80-23, revised 198S).
Histology. The perfusion-fixed arteries were embedded in paraffin and sectioned (2 ~m) every 5 mm.
The sections were stained with Verhoeff van Giesem.
Video images of the light microscopic slides (Zeiss microscope) were projected on a television monitor, total intimal and medial area determined by computer-aided planimetry (Microsystems, Boyce Scientific, St.
Louis, MO), and the intima : media area ratio determined.
Physiological parameters. ~n day zero prior to Alzet pump implantation and day 14 post angioplasty, - arterial blood pressure was measured in anesthetized animals with a Harvard blood pressure monitor (model VT-~ 15C). All animals were placed in metabolic cages one day prior to sacrifice (day 14) for 24-hour urine collections in order to quantitate urinary sodium and cGMP excretion. While in the metabolic cages, ~n;
were not fed but allowed free access to tap water.
WO 96/11688 . PCT/US95tl2366 During days one to thirteen, rats were fed standard rat chow (Purina) and allowed free access to tap water.
Urinary and plasma cGMP was measured using a commercial enzyme immunometric assay (EIA) (Caymen Chem., Ann Arbor, MI). Urine volume was measured gravimetrically, and urine sodium was determined by flame photometry (Instrumentation Laboratory, model 943).
Reagents. Zaprinast was kindly provided by the Monsanto Corporation (St. Louis, MO).
~ tatistics. Statistics were performed using the statistical analysis software package (Instat, GraphPad, San Diego. CA). All data were expressed as mean +
standard error of the mean (SEM). Statistical analysis was performed by two-way analysis of variance and student's t-test was used to evaluate the significance of difference. A probability of less than 0.05 was considered statistically significant.
It has been previously demonstrated that agents which stimulate the production of cGMP such as ANF (23), CNP (13), and NO donors (24) are able to inhibit proliferation of smooth muscle cells in culture.
Therefore, the initial tests were designed to evaluate whether the inhibition of PDE-V by zaprinast, thus increasing endogenous cellular levels of cGMP, would inhibit smooth muscle cell proliferation. Rat aortic smooth muscle cells were seeded at a density of 10,000 cells/well. In the presence of 10% FBS, cell number increased five-fold in three days (FIG.l). In the presence of growth arrest media, no cellular proliferation was noted. One millimolar zaprinast inhibited FBS-induced smooth muscle cell proliferation by approximately 80%, while one tenth this dose _9_ demonstrated little to no inhibition. Theoretically, it is possible that zaprinast treatment decreased the - h~r of cells by causing cellular toxicity or death.
This was not the case since all zaprinast-treated cells effectively excluded trypan blue. Furthermore, daily monitoring of the cell culture media demonstrated no floating or dead cells. These data demonstrate that cellular cGMP is an endogenous inhibitor of VSMC
hyperplasia.
_, Balloon angioplasty of an artery produces intimal thickening and many times results in a significant stenosis. The intimal thickening is secondary to migration of smooth muscle cells from the media into the intima, and subsequent intimal smooth muscle cell proliferation. Since it was demonstrated that zaprinast inhibits smooth muscle cell proliferation in vitro, it was next evaluated whether zaprinast would also inhibit intimal hyperplasia in the injured rat carotid artery.
Zaprinast was a~m; n; stered as a continuous intravenous infusion (25 mg/kg/day) beginning one day prior to angioplasty and continuing until the time of animal sacrifice. As depicted in FIG.2A, zaprinast significantly inhibited intimal hyperplasia by 45%.
Similarly, when intimal hyperplasia was expressed as the ratio of the surface area of the intima to the surface area of the media (microns2), zaprinast inhibited restenosis by 51% (FIG.2B). Representative histological cross-sections of carotid artery from rats treated with either zaprinast or vehicle are shown in FIG.3. These data demonstrate that inhibition of PDE-V with zaprinast is an effective modality to inhibit angioplasty-induced intimal hyperplasia in the rat.
-The pharmacologic profile of zaprinast in rats includes vasorelaxation and sodium excretion (25), but at much higher doses (200 mg/kg/day) than were administered herein. When administered at 25 WO96111688 PCT~S95/12366 mg/kg/day), zaprinast had no effect on mean arterial blood pressure (FIG.4). However, plasma cGMP levels were significantly elevated approximately eight-fold fourteen days after zaprinast treatment (FIG.5).
Therefore, these data confirm the continuous delivery of zaprinast to the rat for the full fourteen days of the test protocol.
Similar to ANF, zaprinast stimulates urinary sodium and cGMP excretion (25). Consistent with these findings, urinary sodium excretion was increased two-fold in the zaprinast treatment group. This natriuresis was accompanied by a similar increase in urinary cGMP
excretion (Table l).
TABLE l Treat~ent (m~q/day) ~ ~lcaMP/vi ) mean + 8EM mean + 8EN
Control 0.9 + o.l 33.0 + 5.5 Zaprinast 2.l + 0.4** 62.5 + lO.3**
** p ~ O . 05 TABLE l shows the urinary sodium and cGMP
excretion in vehicle and zaprinast-treated rats.
Animals were placed into individual metabolic cages 24 hours prior to sacrifice for urine collection.
The administration of the zaprinast to a host or patient subjected to balloon angioplasty can be carried out by conventional means, preferably in formulations with pharmaceutically acceptable diluents and carriers.
The amount to be administered must be an effective amount, that is, an amount which is medically beneficial -CA 02202630 l997-04-l4 but does not present toxic effects which overweigh the advantages which accompany its use.
It is expected that the adult human dose would range upward from about 100mg of the active drug in a daily dose less than about 100mg/Kg of body weight, and preferably in a daily dose of from about 1.5 to about 25mg/Kg of body weight. A suitable route of a~;n;~tration is orally in the form of capsules, tablets, syrups, elixirs and the like, although parenteral administration can also be used such as , e.g., intravenous administration in admixture with physiologic saline and/or suitable buffers. Appropriate formulations of the active drug in pharmaceutically acceptable diluents and carriers in therapeutic dosage form can be prepared by reference to general texts in the field well known to the person skilled in the art such as, e.g., Reminqton's Pharmaceutical Sciences, Ed.
Arthur Osol, 16th ed. 1980, Mack Publishing Co., Easton, PA, and 18th ed. 1990.
Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.
WO 96/11688 PCT/US9~/12366 REFERENCES
1. McBrite, W., Lange, R~., ~ Hillis LD. (1988) N. Engl. I. Mcd. 31t, 1734-1737.
2. Liu, M.W., Roubin, G.S., ~c King, S.B. Jr. (1989) Circulation 79, 1374-l387.
3. Nobuyoshi, M., Kimura, T., Nosaka, H., et al. (1988) J. Am. Coll. Cardiol. 12, 616-623.
4. Serruys, P.W., Luijten, H.E., Beatt, K.J., et al. (1988) Circulation 77, 361-371.
5. Callow, A.D. (1982) Surg. Clin. North Amer. 62, S01-513.
6. McNamara, D.B., Bedi, B., Aurora, H., Tena, L., Ignarro, L.J., Kadowitz, P.l., & Akers, D.L. (1993) Biochem. Biophys. Res. Commun. 193, 291-296.
7. Ignarro, L.J., Buga, G.M., Woot, K.S., Byms, R.E., & Chaudhuri, G.
(1987) Proc. Natl. Acad. Sci. USA 84, 9265-9269.
(1987) Proc. Natl. Acad. Sci. USA 84, 9265-9269.
8. Palmer, R.M.J., Ferrige, A.G., & Moncada, S. (1987) Nature 327, 524-S26.
9. Garg, U.C., & Hassid, A. (1989) J. Clin. Inves~ 83, 1774-1777.
10. Furuya, M., Aisaka, K., Miy_zaki, T., ~onbou, N., Kawashima, K., Ohno, T., Tanalta, S., Minsmino~ N., Kangawa, K., & Matsuo, H. (1993) Biochem. Biophys. Res. Commun. 193, 248-2S3.
11. Stingo, A.J., Clavell, A.L., He~lein, D.M., Wei, C., Dittelkow, M.R., &
Burnett, J.C. Jr. (1992) Am. J. Physiol. 263, H1318-H1321.
WO 96tll688 12. SugJ, S., Itoh, H., Ko~ s~J~ Y., O~awa, Y., Yos~ T.,~t N~kw,K.
(1993) Endocrinology 133, 3038-30~1.
Burnett, J.C. Jr. (1992) Am. J. Physiol. 263, H1318-H1321.
WO 96tll688 12. SugJ, S., Itoh, H., Ko~ s~J~ Y., O~awa, Y., Yos~ T.,~t N~kw,K.
(1993) Endocrinology 133, 3038-30~1.
13. Por~cr, J.G., C-t~ o, R., McEnroe, G., Lcwicki, J.~ Portcr, (1992) ~m 1. Physiol. 263, C1001-C1006.
1~.Fujio, N., Gossard, F., Bayard, F., ~ Trembl~y, 1. (1994) Hyperlnesion 23, 908-913.
IS. Furuya, M., T~l~chis~ M., Minarnitakc, Y., lCit~jim~ Y., Hayashi. Y., Ohnum~, N., Ishihara, T., hlin~mino. N., K~ngaw~, K., ~ Makuo, H.
(1990) ~i~c~le~ Biophys. Res. Co~m~n 170, 201-210.
16. Fu~uya, ~, Yoshid-, ~, Hayashi, Y., O' ~ N., ~in~mino~ N., Kangawa, K., & Matsuo, H. (1990) Biochcm Biophys. Res. Commlm. 177, 927-931.
l7.Lcvin, E.R (1993) Am. J. Physiol. 264, E483-E489.
18. Bcavo, J.~., & Reifsnytcr, D.H. (1990) Trends in Phannacological Scienc~s 11, lS0-lSS. 19. Duntorc, RL., Pratt, P.F., Hellenbcck, W.D., Wassey, M.L., Silver, P.J., ~c Buchhol~. R~. (1990) Europcan J.
Phannacol. 18S, 91-97.
20. Wilkins, W.R, Senle, S L.. & Needleman, P. (1990) J Clin. Inves~ 8S, 1274-1279.
WO 96/llC88 PCrlUS95112366 21. Cho;, E.T., Sehgal, ~ ., Sun, S., Tr~ ni~c~&, J.D., Ry~n, U.S., J~ Callow, .D. (1994) in Modcm Vascul~r Surge~r, od. Ch~ng, J.8. (Spring~
Verlag, Ncw York, NY), Vol. 6, pp. 2840.
22. Choi, E.T., Engel, L., Callow, ~.D., Sun, S., Trachtcnbetg, I.D., Svltor~, S.~ c Ryan, U.S. (199~) J. Vasc. SlJrg. 19. 12S~l3~..
23. ~bell, T.J., Richards, ~.M., Ikram, H.. Espiner, E.~ Yandlc, T.
(1989) Biochcm. Biophys. Rcs. Co.n..~un. 160, 1392-1396.
24. Garg, U.C., ~: Hassid, ~. (1989) J. Clin. In~es~ 83, 1774-1777.
2S. M~allo~ E.G., Palomo, ~.~., Meht~, P., J~ Ollins, G.M. (1989) 3.
Ph~ ~; o' Exp. Therap. 2S 1, 1988-lOOS.
26. Gross~n~n. W., & Baim, D.S. (1991) in Pnnciples of Internal Medicine, ots. Wilson, J.D., Braunwald, E., I#elbacher, K.J., Petcrad~-r, RG., Martin, J.B., Fauci, ~.S., ~ Root, RK. lMcGr~w-Hill, New York, NY), Vol. 12, pp. 877-879.
27. Fingcrle, J., lohn~n, R, Clowes, ~.W., MAjesky, M.W., ~ Reidy, M.~.
(1989) Proc. Natl. Acat. Sci. US~ 86, 8412-8416.
28. Fuster, V., Ra~imo~. L., P~imo~ l.J., & Chesebro, J.H. (1992) New Engl. J. Met. 326, 242-318.
29. Lam, J.Y.T., Chcsebro, J.H., & Steele, P.~ (}g91) 84, 814-820.
30. J~ckson, C.L.. Bush, RC., ~ Bowycr, D.E. (1988) ~erosclcrosis 69, 1 15-122.
31. Mullcr, D.W., Ellis, S.G., ~ Topol, E.J. (1991)1. ~m. Coll. Cudiol. 17(6 Suppl B), 126B 13lB.
32. p~ gi,~, Jacob. J.H., ~ r,~,,, I.RKricger, J.E., Dzau, V.J., ~ Pr-tt, R.E. (1990) Tly~,cne,~s;on 16, 343S-3S2.
33. FL~con, D.P. (1992) C;rC~IA~;OI- 86, 100-110.
34. Weber. A.~., Strobach, H., ~ Schror, K. (1993) Elopcan J. Ph~ r ~ Dl~
2~7; 29-37.
3S. Southgste, K., & Newby, ~.C. (1990) ~lhc.usclerosis 82, 113-123.
36. Rosenzwcig, ~., & Seitman, C.E. (1991) ~nnu. Re-~. Biochem. 60, 229-2SS.
37. Duntore, RLPran. P.F., O'Connor, B., Buchllol~. R~ Paguni, E.D.
(1991) Europc~ J. Pl~ ~' 200, 83-8?.
38. Andcrson, T.L., & Vingc, E. (1991) J. Cardiovasc, Phannacol. 18, 237-242.
1~.Fujio, N., Gossard, F., Bayard, F., ~ Trembl~y, 1. (1994) Hyperlnesion 23, 908-913.
IS. Furuya, M., T~l~chis~ M., Minarnitakc, Y., lCit~jim~ Y., Hayashi. Y., Ohnum~, N., Ishihara, T., hlin~mino. N., K~ngaw~, K., ~ Makuo, H.
(1990) ~i~c~le~ Biophys. Res. Co~m~n 170, 201-210.
16. Fu~uya, ~, Yoshid-, ~, Hayashi, Y., O' ~ N., ~in~mino~ N., Kangawa, K., & Matsuo, H. (1990) Biochcm Biophys. Res. Commlm. 177, 927-931.
l7.Lcvin, E.R (1993) Am. J. Physiol. 264, E483-E489.
18. Bcavo, J.~., & Reifsnytcr, D.H. (1990) Trends in Phannacological Scienc~s 11, lS0-lSS. 19. Duntorc, RL., Pratt, P.F., Hellenbcck, W.D., Wassey, M.L., Silver, P.J., ~c Buchhol~. R~. (1990) Europcan J.
Phannacol. 18S, 91-97.
20. Wilkins, W.R, Senle, S L.. & Needleman, P. (1990) J Clin. Inves~ 8S, 1274-1279.
WO 96/llC88 PCrlUS95112366 21. Cho;, E.T., Sehgal, ~ ., Sun, S., Tr~ ni~c~&, J.D., Ry~n, U.S., J~ Callow, .D. (1994) in Modcm Vascul~r Surge~r, od. Ch~ng, J.8. (Spring~
Verlag, Ncw York, NY), Vol. 6, pp. 2840.
22. Choi, E.T., Engel, L., Callow, ~.D., Sun, S., Trachtcnbetg, I.D., Svltor~, S.~ c Ryan, U.S. (199~) J. Vasc. SlJrg. 19. 12S~l3~..
23. ~bell, T.J., Richards, ~.M., Ikram, H.. Espiner, E.~ Yandlc, T.
(1989) Biochcm. Biophys. Rcs. Co.n..~un. 160, 1392-1396.
24. Garg, U.C., ~: Hassid, ~. (1989) J. Clin. In~es~ 83, 1774-1777.
2S. M~allo~ E.G., Palomo, ~.~., Meht~, P., J~ Ollins, G.M. (1989) 3.
Ph~ ~; o' Exp. Therap. 2S 1, 1988-lOOS.
26. Gross~n~n. W., & Baim, D.S. (1991) in Pnnciples of Internal Medicine, ots. Wilson, J.D., Braunwald, E., I#elbacher, K.J., Petcrad~-r, RG., Martin, J.B., Fauci, ~.S., ~ Root, RK. lMcGr~w-Hill, New York, NY), Vol. 12, pp. 877-879.
27. Fingcrle, J., lohn~n, R, Clowes, ~.W., MAjesky, M.W., ~ Reidy, M.~.
(1989) Proc. Natl. Acat. Sci. US~ 86, 8412-8416.
28. Fuster, V., Ra~imo~. L., P~imo~ l.J., & Chesebro, J.H. (1992) New Engl. J. Met. 326, 242-318.
29. Lam, J.Y.T., Chcsebro, J.H., & Steele, P.~ (}g91) 84, 814-820.
30. J~ckson, C.L.. Bush, RC., ~ Bowycr, D.E. (1988) ~erosclcrosis 69, 1 15-122.
31. Mullcr, D.W., Ellis, S.G., ~ Topol, E.J. (1991)1. ~m. Coll. Cudiol. 17(6 Suppl B), 126B 13lB.
32. p~ gi,~, Jacob. J.H., ~ r,~,,, I.RKricger, J.E., Dzau, V.J., ~ Pr-tt, R.E. (1990) Tly~,cne,~s;on 16, 343S-3S2.
33. FL~con, D.P. (1992) C;rC~IA~;OI- 86, 100-110.
34. Weber. A.~., Strobach, H., ~ Schror, K. (1993) Elopcan J. Ph~ r ~ Dl~
2~7; 29-37.
3S. Southgste, K., & Newby, ~.C. (1990) ~lhc.usclerosis 82, 113-123.
36. Rosenzwcig, ~., & Seitman, C.E. (1991) ~nnu. Re-~. Biochem. 60, 229-2SS.
37. Duntore, RLPran. P.F., O'Connor, B., Buchllol~. R~ Paguni, E.D.
(1991) Europc~ J. Pl~ ~' 200, 83-8?.
38. Andcrson, T.L., & Vingc, E. (1991) J. Cardiovasc, Phannacol. 18, 237-242.
Claims (2)
1. Use of a small but inhibitorily effective amount of zaprinast for preparing a medicament for inhibiting intimal hyperplasia in a warm-blooded mammal following balloon angio-plasty.
2. Use according to Claim 1 wherein the amount of zaprinast administered is from about 1.5 to about 25 mg/Kg per day.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/324,816 US5521191A (en) | 1994-10-17 | 1994-10-17 | Method for treatment of arterial stenosis |
US08/324,816 | 1994-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2202630A1 true CA2202630A1 (en) | 1996-04-25 |
Family
ID=23265225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002202630A Abandoned CA2202630A1 (en) | 1994-10-17 | 1995-10-10 | Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis |
Country Status (6)
Country | Link |
---|---|
US (1) | US5521191A (en) |
EP (1) | EP0787001A1 (en) |
JP (1) | JPH10507449A (en) |
AU (1) | AU3728095A (en) |
CA (1) | CA2202630A1 (en) |
WO (1) | WO1996011688A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6663881B2 (en) | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6197789B1 (en) | 1995-06-07 | 2001-03-06 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
US5858694A (en) * | 1997-05-30 | 1999-01-12 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of cancerous lesions |
US6656452B1 (en) | 1997-10-21 | 2003-12-02 | The General Hospital Corporation | Use of inhaled NO as anti-inflammatory agent |
US6417208B1 (en) * | 1999-02-05 | 2002-07-09 | Albert Einstein College Of Medicine Of Yeshiva University | Method of identification of inhibitors of PDE1C |
WO2010118352A1 (en) | 2009-04-09 | 2010-10-14 | Arizona Board Of Reagents On Behalf Of The University Of Arizona | Cellular seeding and co-culture of a three dimensional fibroblast construct |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496544A (en) * | 1983-11-10 | 1985-01-29 | Washington University | Atrial Peptides |
US5270047A (en) * | 1991-11-21 | 1993-12-14 | Kauffman Raymond F | Local delivery of dipyridamole for the treatment of proliferative diseases |
-
1994
- 1994-10-17 US US08/324,816 patent/US5521191A/en not_active Expired - Fee Related
-
1995
- 1995-10-10 CA CA002202630A patent/CA2202630A1/en not_active Abandoned
- 1995-10-10 JP JP8513242A patent/JPH10507449A/en not_active Ceased
- 1995-10-10 WO PCT/US1995/012366 patent/WO1996011688A1/en not_active Application Discontinuation
- 1995-10-10 AU AU37280/95A patent/AU3728095A/en not_active Abandoned
- 1995-10-10 EP EP95935152A patent/EP0787001A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0787001A1 (en) | 1997-08-06 |
AU3728095A (en) | 1996-05-06 |
US5521191A (en) | 1996-05-28 |
WO1996011688A1 (en) | 1996-04-25 |
JPH10507449A (en) | 1998-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU781084B2 (en) | Nicotine in therapeutic angiogenesis and vasculogenesis | |
CA2641815C (en) | Method of treatment for muscular dystrophy | |
CA2202630A1 (en) | Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis | |
KR100701904B1 (en) | Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist | |
AU778386B2 (en) | Nicotine receptor agonists in stem cell and progenitor cell recruitment | |
EP0543653A1 (en) | Dipyridamole for the treatment of proliferative diseases | |
US20080300253A1 (en) | Treatment of inflammatory disorders with praziquantel | |
JPH10114681A (en) | Anti-fibrosis agent | |
JP2001502659A (en) | Combination therapy for the treatment of erectile dysfunction | |
EP1503755A1 (en) | Zonisamide use in obesity and eating disorders | |
US7998460B2 (en) | Prevention of deficits in neurogenesis with anti-inflammatory agents | |
JP2003523944A (en) | Antiviral therapy using P-glycoprotein modifiers | |
JP2007532671A (en) | Combination therapy comprising an adenosine A1 receptor antagonist and an aldosterone inhibitor | |
KR20050106038A (en) | Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases | |
JP2006502087A (en) | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | |
US5767103A (en) | Nitric oxide sequestrant | |
EP2252286B1 (en) | Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria | |
JP2002536325A (en) | L-arginine-based formulations for treating diseases and methods of using the same | |
Castronuovo Jr et al. | Cytokine therapy for arterial restenosis: inhibition of neointimal hyperplasia by gamma-interferon | |
US20030064932A1 (en) | Methods of treatment comprising administration of Substance P | |
EA001931B1 (en) | Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the treatment or prevention of restenosis | |
US5486519A (en) | Method for treatment of acute renal failure | |
WO1995031204A1 (en) | Cobalamins as nitric oxide sequestrants | |
WO2023130161A1 (en) | Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda) along with an additional active agent | |
JP2000191540A (en) | Pharmacotherapy for restenosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20070724 |